Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994893487> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2994893487 endingPage "S514" @default.
- W2994893487 startingPage "S514" @default.
- W2994893487 abstract "Estimate the societal cost of life lost from reimbursement delays of four novel medications for treatment of melanoma, lung, and breast cancers in select ex-U.S. settings. We developed an economic model to predict the societal value of life lost from reimbursement delays, incorporating: 1) length of delay from regulatory to HTA to provincial approval of trastuzumab, crizotinib, ipilimumab, or pembrolizumab in Canada, Italy, and Australia; 2) prevalence of patients matching medications’ indications; 4) incident cases arising during HTA and Provincial delays; and 5) incremental overall survival, along with the societal value of increased survival, associated with the medications compared to standard of care. HTA processes generally delayed reimbursement over 400 days post-regulatory approval, with Australia taking the longest time. Canadian provincial delays commonly contributed 150+ days, post HTA recommendation, until patient access was granted. The societal value of life days lost per patient ranged from $32,148 for ipilimumab in Italy to $101,565 for crizotinib in Australia, varying based on disease burden and country-specific values of life-years, along with incremental overall survival for each drug. The societal cost of HTA delays varied by country and medication, but was substantial, ranging from $8.1 million (81 life years lost) for trastuzumab in Canada to $118 million (1,179 life years lost) for ipilimumab in Australia. The model results were sensitive to two key parameters: 1) total prevalent patients at the time of regulatory approval experiencing the deleterious impact of reimbursement delays; and 2) drug market shares following reimbursement approval. While the magnitude of cost savings varied by up to 75%, directionality remained consistent. Results of this model demonstrate that delays in reimbursement of clinically superior oncology medications, deemed safe and effective by regulatory bodies, can exacerbate clinical burden for patients through loss of life, translating to significant economic detriments to society." @default.
- W2994893487 created "2019-12-26" @default.
- W2994893487 creator A5014971648 @default.
- W2994893487 creator A5016380667 @default.
- W2994893487 creator A5024533933 @default.
- W2994893487 creator A5040448598 @default.
- W2994893487 creator A5045467906 @default.
- W2994893487 creator A5054014348 @default.
- W2994893487 creator A5058077403 @default.
- W2994893487 creator A5080398017 @default.
- W2994893487 creator A5082531351 @default.
- W2994893487 creator A5086186192 @default.
- W2994893487 date "2019-11-01" @default.
- W2994893487 modified "2023-09-26" @default.
- W2994893487 title "PCN402 THE CLINICAL AND ECONOMIC CONSEQUENCES OF DELAYS IN REIMBURSEMENT FOR SELECT NOVEL CANCER THERAPEUTICS IN CANADA, ITALY, AND AUSTRALIA" @default.
- W2994893487 doi "https://doi.org/10.1016/j.jval.2019.09.597" @default.
- W2994893487 hasPublicationYear "2019" @default.
- W2994893487 type Work @default.
- W2994893487 sameAs 2994893487 @default.
- W2994893487 citedByCount "0" @default.
- W2994893487 crossrefType "journal-article" @default.
- W2994893487 hasAuthorship W2994893487A5014971648 @default.
- W2994893487 hasAuthorship W2994893487A5016380667 @default.
- W2994893487 hasAuthorship W2994893487A5024533933 @default.
- W2994893487 hasAuthorship W2994893487A5040448598 @default.
- W2994893487 hasAuthorship W2994893487A5045467906 @default.
- W2994893487 hasAuthorship W2994893487A5054014348 @default.
- W2994893487 hasAuthorship W2994893487A5058077403 @default.
- W2994893487 hasAuthorship W2994893487A5080398017 @default.
- W2994893487 hasAuthorship W2994893487A5082531351 @default.
- W2994893487 hasAuthorship W2994893487A5086186192 @default.
- W2994893487 hasBestOaLocation W29948934871 @default.
- W2994893487 hasConcept C121608353 @default.
- W2994893487 hasConcept C126322002 @default.
- W2994893487 hasConcept C143998085 @default.
- W2994893487 hasConcept C160735492 @default.
- W2994893487 hasConcept C162324750 @default.
- W2994893487 hasConcept C2776232967 @default.
- W2994893487 hasConcept C2776256026 @default.
- W2994893487 hasConcept C2777701055 @default.
- W2994893487 hasConcept C2779422266 @default.
- W2994893487 hasConcept C2779703844 @default.
- W2994893487 hasConcept C2779786085 @default.
- W2994893487 hasConcept C2781433595 @default.
- W2994893487 hasConcept C50522688 @default.
- W2994893487 hasConcept C512399662 @default.
- W2994893487 hasConcept C530470458 @default.
- W2994893487 hasConcept C71924100 @default.
- W2994893487 hasConceptScore W2994893487C121608353 @default.
- W2994893487 hasConceptScore W2994893487C126322002 @default.
- W2994893487 hasConceptScore W2994893487C143998085 @default.
- W2994893487 hasConceptScore W2994893487C160735492 @default.
- W2994893487 hasConceptScore W2994893487C162324750 @default.
- W2994893487 hasConceptScore W2994893487C2776232967 @default.
- W2994893487 hasConceptScore W2994893487C2776256026 @default.
- W2994893487 hasConceptScore W2994893487C2777701055 @default.
- W2994893487 hasConceptScore W2994893487C2779422266 @default.
- W2994893487 hasConceptScore W2994893487C2779703844 @default.
- W2994893487 hasConceptScore W2994893487C2779786085 @default.
- W2994893487 hasConceptScore W2994893487C2781433595 @default.
- W2994893487 hasConceptScore W2994893487C50522688 @default.
- W2994893487 hasConceptScore W2994893487C512399662 @default.
- W2994893487 hasConceptScore W2994893487C530470458 @default.
- W2994893487 hasConceptScore W2994893487C71924100 @default.
- W2994893487 hasLocation W29948934871 @default.
- W2994893487 hasOpenAccess W2994893487 @default.
- W2994893487 hasPrimaryLocation W29948934871 @default.
- W2994893487 hasRelatedWork W2078328981 @default.
- W2994893487 hasRelatedWork W2275306405 @default.
- W2994893487 hasRelatedWork W2396867169 @default.
- W2994893487 hasRelatedWork W2434826532 @default.
- W2994893487 hasRelatedWork W2541710827 @default.
- W2994893487 hasRelatedWork W2611120829 @default.
- W2994893487 hasRelatedWork W2995806561 @default.
- W2994893487 hasRelatedWork W3026962740 @default.
- W2994893487 hasRelatedWork W3203425821 @default.
- W2994893487 hasRelatedWork W4317934829 @default.
- W2994893487 hasVolume "22" @default.
- W2994893487 isParatext "false" @default.
- W2994893487 isRetracted "false" @default.
- W2994893487 magId "2994893487" @default.
- W2994893487 workType "article" @default.